Open AccessHepatitis C virus, directly acting antivirals and Guillain-Barré syndrome
Author(s) -
Manish R Balwani,
Charulata Bawankule,
Vishal V Ramteke,
Amit Pasari
Publication year - 2018
Publication title -
saudi journal of kidney diseases and transplantation/našrat amraḍ wa zira'aẗ al-kulaẗ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.268
H-Index - 30
eISSN - 2320-3838
pISSN - 1319-2442
DOI - 10.4103/1319-2442.243969
Subject(s) - medicine , daclatasvir , guillain barre syndrome , etiology , sofosbuvir , differential diagnosis , weakness , hepatitis c virus , intensive care medicine , pneumonia , virus , pediatrics , virology , surgery , ribavirin , pathology
Guillain-Barré syndrome (GBS) has been associated with both infective and noninfective etiologies. It is usually preceded by acute gastrointestinal or respiratory infections. We report an unusual case of GBS in a hepatitis C virus-positive hemodialysis (HD)-dependent patient who was being treated with sofosbuvir and daclatasvir along with antitubercular drugs for pulmonary tuberculosis. One should keep GBS in the differential diagnosis in HD patients whenever patient presents with lower limb weakness. Early diagnosis will help in timely initiation of treatment which is crucial to treat GBS.